

(51) International Patent Classification:

A61K 31/713 (2006.01) A61K 33/00 (2006.01)
 A61P 5/50 (2006.01) C07K 16/40 (2006.01)
 A61K 39/395 (2006.01) A61K 31/427 (2006.01)
 A61K 31/7064 (2006.01) A61K 31/197 (2006.01)
 A61K 31/44 (2006.01) A61K 38/28 (2006.01)
 C12Q 1/48 (2006.01) A61K 38/22 (2006.01)
 G01N 33/48 (2006.01) A61K 31/455 (2006.01)
 A61K 31/416 (2006.01)

(21) International Application Number:

PCT/SG2012/000169

(22) International Filing Date:

14 May 2012 (14.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201103478-2 13 May 2011 (13.05.2011)

SG

(71) Applicant (for all designated States except US):

AGENCY FOR SCIENCE, TECHNOLOGY AND RE-
 SEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connex-
 is, Singapore 138632 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COHEN, Stephen

Michael [SG/SG]; c/o Institute of Molecular and Cell Bio-
 logic, #08-06, 61 Biopolis Drive, Proteos, Singapore

138673 (SG). ZHANG, Wei [SG/SG]; c/o Institute of Mo-
 lecular and Cell Biology, #08-06, 61 Biopolis Drive, Pro-
 teos, Singapore 138673 (SG).

(74) Agent: ELLA CHEONG SPRUSON & FERGUSON

(SINGAPORE) PTE LTD; P. O. Box 1531, Robinson
 Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD,
 SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME




FIG. 1(b)

(57) **Abstract:** The present invention relates to a method of treating or preventing insulin resistance syndrome in an animal body by administering an inhibitor of *protein kinase RNA-like endoplasmic reticulum kinase* (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof or a method of reducing activity of transcription factors of the FOXO family (Foxo 1, 3a, 4 and 6) by administering an inhibitor of *protein kinase RNA-like endoplasmic reticulum kinase* (PERK) gene, or a functional variant thereof, or an inhibitor of PERK protein or a functional variant thereof. The present invention also relates to different compounds and methods for using PERK gene or PERK protein.



Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))